Marta Wayt, DO
Internal Medicine · Kingsport, TNNPI 1316903099
Payments from drug & device makers
Across 211 payments — averaging $14.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$763
- GSK$456
- AbbVie$328
- Pfizer$132
- Amgen$99
- Exact Sciences$86
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,964100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 62 | $763 |
| GSK | 34 | $456 |
| AbbVie(2 entities) | 25 | $328 |
| Pfizer | 10 | $132 |
| Amgen(2 entities) | 7 | $99 |
| Exact Sciences | 4 | $86 |
| Astellas Pharma US Inc | 4 | $80 |
| Lilly USA, LLC | 5 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $73 |
| Supernus Pharmaceuticals, Inc. | 3 | $70 |
| AstraZeneca | 5 | $66 |
| Kowa Pharmaceuticals America, Inc. | 4 | $62 |
| Johnson & Johnson | 5 | $61 |
| Abbott | 1 | $60 |
| Boehringer Ingelheim | 4 | $55 |
| Novartis | 4 | $53 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Acadia Pharmaceuticals Inc | 3 | $42 |
| Tactile Systems Technology Inc | 2 | $36 |
| Dexcom, Inc. | 2 | $25 |
| Merck | 2 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Gilead | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2 |
How this compares
$2,964 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 1,262 | $262,245 |
| EliquisApixaban | 681 | $214,720 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 664 | $198,663 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 646 | $188,506 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $117,017 |
| FarxigaDapagliflozin Propanediol | 232 | $87,034 |
| OzempicSemaglutide | 82 | $83,531 |
| XifaxanRifaximin | 38 | $78,794 |
| ProliaDenosumab | 40 | $74,199 |
| MounjaroTirzepatide | 40 | $43,660 |
| JardianceEmpagliflozin | 121 | $41,296 |
| LinzessLinaclotide | 43 | $35,639 |
| JanuviaSitagliptin Phosphate | 175 | $33,122 |
| XareltoRivaroxaban | 118 | $28,417 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $27,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Trelegy Ellipta, Breo Ellipta | $456 | $585,5952,088 claims |
| PfizerEliquis, Abrysvo | $132 | $413,3831,345 claims |
| Novo NordiskOzempic, Rybelsus | $763 | $99,87995 claims |
| AstraZenecaFarxiga | $66 | $87,034232 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $22 | $78,79438 claims |
| AmgenProlia | $99 | $74,19940 claims |
| Lilly USA, LLCMounjaro, Trulicity | $79 | $70,60971 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $55 | $59,737144 claims |
| MerckJanuvia, Lagevrio (Eua), Janumet | $25 | $50,803203 claims |
| AbbVieLinzess, Restasis | $328 | $45,71159 claims |
| Johnson & JohnsonXarelto | $61 | $28,417118 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $18,82126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Kingsport
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- David MorinKingsport$1.4M
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.